Growth equity

Some fear GPs are at risk of overpromising and underdelivering on AI’s ability to drive topline growth.

Investors are keeping a close eye on AI, defence and liquidity dynamics but require managers to clearly distinguish their strategies from those available elsewhere, according to conversations at PEI Group's latest Investor Council gathering.

The $250m sought for Vertex Growth III would make it at least 40% smaller than its predecessor.

The Keystone strategy is expected to remain relevant across fundraising cycles, managing partner Ian Charles and partner Charlie Tingue tell PEI.

The institution aims to increase its allocations to AI-focused investments, private credit and core-plus infrastructure assets by March 2031.

The manager of Novo Nordisk Foundation’s $36bn of investments is expanding its planetary health portfolio and mulling carving out an allocation for private equity GPs to run, according to partner Aleks Engel.

The $1.8trn pension saw its PE portfolio grow by around $1.4bn year-on-year, per its latest annual report.

China’s private equity reset could yield a more disciplined opportunity set for LPs who retain conviction in the market.

Private capital should not be viewed as a replacement for government funding, but rather as a catalyst that brings commercial discipline and scale, according to the director general of the Royal United Services Institute speaking at a UK Private Capital event.

Dutch manager Main Capital's focus on 'mission-critical companies' means it is less affected by AI-driven volatility in the wider market, managing partner Sjoerd Aarts tells PEI.